深圳85后博士夫妻，打造手术机器人“全能选手”，刚刚敲钟，市值196亿

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (stock code: 02675.HK) officially listed on the Hong Kong Stock Exchange on January 8, 2026, becoming a representative of domestic players in the surgical robot sector, raising approximately HKD 1.2 billion with a post-IPO market capitalization of around HKD 21.9 billion (approximately RMB 19.6 billion) [2]. Group 1: Company Overview - The founders, Wang Jianchen and Gao Yuanqian, transformed a startup into a global player in the surgical robot field within nine years, becoming the first Chinese company and the second globally to offer a full range of products in multi-port, single-port, and natural orifice categories, second only to Intuitive Surgical [4]. - The IPO attracted 13 cornerstone investors, including the Abu Dhabi Investment Authority (ADIA), UBS Asset Management, Tencent, and others, collectively subscribing to USD 75 million, accounting for 48.7% of the total fundraising [4][6]. - Prior to the IPO, the company completed eight rounds of financing, raising over RMB 2 billion, with a valuation increase from RMB 43 million in early stages to nearly RMB 15 billion before the IPO [4][6]. Group 2: Product Development and Market Position - Precision Medical's core competitive advantage lies in its comprehensive product line covering multi-port, single-port, and bronchoscopic robots, all developed in-house, making it the second company globally to achieve this [25]. - The company’s products are priced at 60-70% of imported brands, with 100% self-research and 85% localized supply chain, providing timely local service and superior operational performance [25][36]. - The surgical robot market is projected to grow significantly, with the global market expected to reach USD 84.2 billion by 2033, and the Chinese market anticipated to grow to RMB 102 billion by 2033, reflecting a compound annual growth rate of 34.3% [36]. Group 3: Financial Performance and Growth - From 2023 to the first half of 2025, the company's revenue surged from RMB 48.04 million to RMB 149.3 million, marking a growth rate of nearly 400%, with gross profit reaching RMB 93.85 million in the first half of 2025 [27][29]. - The net loss narrowed from RMB 1.33 billion in 2024 to RMB 890.87 million in the same period, indicating a clear trend of improving financial health [27][29]. Group 4: Clinical and Market Strategy - To address initial skepticism from surgeons regarding domestic surgical robots, the company offered free clinical trials and conducted systematic training at top institutions, gradually gaining trust [20]. - The company has established a comprehensive clinical support system, ensuring that its products are effectively utilized in hospitals, which includes a three-tier training network for doctors [33][34]. - By 2025, the company had expanded its products to over 220 top-tier hospitals across China and exported to 26 countries, achieving a cumulative installation of over 80 units and assisting in over 14,000 surgeries [27][30].